Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laure Elens

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Pharmacogenomics|August 27, 2014
Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotypeMaja Matic, Sinno H P Simons, Richard A van Lingen, et al.
Therapeutic Drug Monitoring|September 21, 2013
Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelinesLaure Elens, Arnaud Capron, Ron H N van Schaik, et al.
Pharmacogenomics|August 13, 2013
Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam StudyCatherine E de Keyser, Matthijs L Becker, André G Uitterlinden, et al.
Frontiers in Pharmacology|June 24, 2017
Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney TransplantationJean-Baptiste Woillard, Michel Mourad, Michael Neely, et al.
Scientific Reports|July 1, 2025
Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional studyJulien De Greef, Khoi Nguyen Nguyen, Matthias Van Hul, et al.
Clinical Pharmacokinetics|January 5, 2017
A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population ApproachFranc Andreu, Helena Colom, Laure Elens, et al.
Frontiers in Genetics|July 26, 2021
<i>CYP3A4</i> Genotyping in Clinical Practice: Ready for Implementation?Tessa A M Mulder, Ruben A G van Eerden, Mirjam de With, et al.
Pharmacogenetics and Genomics|January 18, 2013
Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycinLaure Elens, Annemieke J M Nieuweboer, Stephen J Clarke, et al.
BMJ Open|June 7, 2026
ElucidatiNg Immunosuppressant pharmacokinetic variabilities by investigating Gut Microbiome modulations After kidney transplantation (ENIGMA): study protocol of a prospective longitudinal trialAlice Barbé, Lidvine Boland, Nada Kanaan, et al.
Therapeutic Drug Monitoring|September 25, 2013
Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patientsLaure Elens, Dennis A Hesselink, Rachida Bouamar, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Pharmacogenomics|August 27, 2014
Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotypeMaja Matic, Sinno H P Simons, Richard A van Lingen, et al.
Therapeutic Drug Monitoring|September 21, 2013
Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelinesLaure Elens, Arnaud Capron, Ron H N van Schaik, et al.
Pharmacogenomics|August 13, 2013
Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam StudyCatherine E de Keyser, Matthijs L Becker, André G Uitterlinden, et al.
Frontiers in Pharmacology|June 24, 2017
Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney TransplantationJean-Baptiste Woillard, Michel Mourad, Michael Neely, et al.
Scientific Reports|July 1, 2025
Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional studyJulien De Greef, Khoi Nguyen Nguyen, Matthias Van Hul, et al.
Clinical Pharmacokinetics|January 5, 2017
A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population ApproachFranc Andreu, Helena Colom, Laure Elens, et al.
Frontiers in Genetics|July 26, 2021
<i>CYP3A4</i> Genotyping in Clinical Practice: Ready for Implementation?Tessa A M Mulder, Ruben A G van Eerden, Mirjam de With, et al.
Pharmacogenetics and Genomics|January 18, 2013
Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycinLaure Elens, Annemieke J M Nieuweboer, Stephen J Clarke, et al.
BMJ Open|June 7, 2026
ElucidatiNg Immunosuppressant pharmacokinetic variabilities by investigating Gut Microbiome modulations After kidney transplantation (ENIGMA): study protocol of a prospective longitudinal trialAlice Barbé, Lidvine Boland, Nada Kanaan, et al.
Therapeutic Drug Monitoring|September 25, 2013
Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patientsLaure Elens, Dennis A Hesselink, Rachida Bouamar, et al.
Pageof 9